207 related articles for article (PubMed ID: 11037819)
1. Therapeutic efficacy of Th1 and Th2 L-selectin--CD4+ tumor-reactive T cells.
To WC; Seeley BM; Barthel SW; Shu S
Laryngoscope; 2000 Oct; 110(10 Pt 1):1648-54. PubMed ID: 11037819
[TBL] [Abstract][Full Text] [Related]
2. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
Kagamu H; Shu S
J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
[TBL] [Abstract][Full Text] [Related]
3. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
4. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
5. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
6. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
Sussman JJ; Parihar R; Winstead K; Finkelman FD
Cancer Res; 2004 Dec; 64(24):9124-30. PubMed ID: 15604282
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
8. gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
10. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
11. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
12. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
13. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
14. Th1 CD4+ cells adoptively transfer experimental hypersensitivity pneumonitis.
Schuyler M; Gott K; Cherne A; Edwards B
Cell Immunol; 1997 May; 177(2):169-75. PubMed ID: 9178644
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
16. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.
Pinto RA; Arredondo SM; Bono MR; Gaggero AA; Díaz PV
Pediatrics; 2006 May; 117(5):e878-86. PubMed ID: 16618789
[TBL] [Abstract][Full Text] [Related]
17. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
18. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
19. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
20. Transplant tolerance associated with a Th1 response and not broken by IL-4, IL-5, and TGF-beta blockade or Th1 cytokine administration.
Plain KM; Boyd R; Verma ND; Robinson CM; Tran GT; Hodgkinson SJ; Hall BM
Transplantation; 2007 Mar; 83(6):764-73. PubMed ID: 17414711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]